Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025
03:42pm, Friday, 03'rd Jan 2025
Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due to e
Halozyme: Recent Approvals Alter My Appetite
02:41am, Tuesday, 31'st Dec 2024
Halozyme's attempt to acquire Evotec was a bold move to diversify revenue but was ultimately unsuccessful, impacting HALO's stock price. Despite a CRL for Rybrevant, Halozyme's technology saw success
SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10% (Hum
SAN DIEGO , Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated
Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
01:46pm, Monday, 23'rd Dec 2024
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HALO or FOLD: Which Is the Better Value Stock Right Now?
12:46pm, Monday, 23'rd Dec 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two comp
How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08%
10:57am, Monday, 16'th Dec 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Halozyme Therapeutics (HALO). While the effectiveness of this highly sought-after metric is questionab
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
10:46am, Wednesday, 11'th Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
10:50am, Monday, 09'th Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now?
10:46am, Monday, 09'th Dec 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now
01:46pm, Thursday, 05'th Dec 2024
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
HALO vs. FOLD: Which Stock Is the Better Value Option?
12:41pm, Thursday, 05'th Dec 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two stocks is more attractive
Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year?
10:45am, Thursday, 05'th Dec 2024
Here is how Halozyme Therapeutics (HALO) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Halozyme to Present at Upcoming Investor Conferences
08:30am, Wednesday, 27'th Nov 2024
SAN DIEGO , Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host invest
